These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23607811)

  • 1. 3D QSAR and docking studies of various amido and benzyl-substituted 3-amino-4-(2-cyanopyrrolidide)pyrrolidinyl analogs as DPP-IV inhibitors.
    Agrawal R; Jain P; Dikshit SN; Jain S
    Protein Pept Lett; 2013 Sep; 20(9):1066-78. PubMed ID: 23607811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3D QSAR and docking study of gliptin derivatives as DPP-IV inhibitors.
    Agrawal R; Jain P; Dikshit SN; Bahare RS
    Comb Chem High Throughput Screen; 2013 May; 16(4):249-73. PubMed ID: 23305140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D QSAR of aminophenyl benzamide derivatives as histone deacetylase inhibitors.
    Mahipal ; Tanwar OP; Karthikeyan C; Moorthy NS; Trivedi P
    Med Chem; 2010 Sep; 6(5):277-85. PubMed ID: 20977417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2
    Musoev A; Numonov S; You Z; Gao H
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31394858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacophore generation, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on benzamide analogues as FtsZ inhibitors.
    Tripathy S; Azam MA; Jupudi S; Sahu SK
    J Biomol Struct Dyn; 2018 Sep; 36(12):3218-3230. PubMed ID: 28938860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ligand-based pharmacophore detection, screening of potential gliptins and docking studies to get effective antidiabetic agents.
    Agrawal R; Jain P; Dikshit SN
    Comb Chem High Throughput Screen; 2012 Dec; 15(10):849-76. PubMed ID: 23140189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a robust QSAR model to predict the affinity of pyrrolidine analogs for dipeptidyl peptidase IV (DPP- IV).
    Paliwal S; Seth D; Yadav D; Yadav R; Paliwal S
    J Enzyme Inhib Med Chem; 2011 Feb; 26(1):129-40. PubMed ID: 21299434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of DPP IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening.
    Al-Masri IM; Mohammad MK; Taha MO
    ChemMedChem; 2008 Nov; 3(11):1763-79. PubMed ID: 18989859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacophore generation and atom-based 3D-QSAR of novel quinoline-3-carbonitrile derivatives as Tpl2 kinase inhibitors.
    Teli MK; Rajanikant GK
    J Enzyme Inhib Med Chem; 2012 Aug; 27(4):558-70. PubMed ID: 21851209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Different Dietary Flavonoids on Dipeptidyl Peptidase-IV Activity and Expression: Insights into Structure-Activity Relationship.
    Gao F; Fu Y; Yi J; Gao A; Jia Y; Cai S
    J Agric Food Chem; 2020 Oct; 68(43):12141-12151. PubMed ID: 33063510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine.
    Chaudhari HK; Pahelkar A
    Infect Disord Drug Targets; 2019; 19(2):145-166. PubMed ID: 30324898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CoMFA and CoMSIA of diverse pyrrolidine analogues as dipeptidyl peptidase IV inhibitors: active site requirements.
    Murugesan V; Sethi N; Prabhakar YS; Katti SB
    Mol Divers; 2011 May; 15(2):457-66. PubMed ID: 20737212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combination of pharmacophore modeling, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on PDE4 enzyme inhibitors.
    Tripuraneni NS; Azam MA
    J Biomol Struct Dyn; 2016 Nov; 34(11):2481-92. PubMed ID: 26587754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular docking and 3D-QSAR studies on beta-phenylalanine derivatives as dipeptidyl peptidase IV inhibitors.
    Jiang YK
    J Mol Model; 2010 Jul; 16(7):1239-49. PubMed ID: 20069322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration of DPP-IV inhibitors with a novel scaffold by multistep in silico screening.
    Uchida T; Wakasugi M; Kitamura T; Yamamoto T; Asakura M; Fujiwara R; Itoh T; Fujii H; Hirono S
    J Mol Graph Model; 2018 Jan; 79():254-263. PubMed ID: 29274572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of TZD Scaffold as Potential ARIs: Pharmacophore Modeling, Atom-based 3D QSAR and Docking Studies.
    Dahiya L; Mahapatra MK; Kaur R; Kumar V; Kumar M
    Comb Chem High Throughput Screen; 2017; 20(4):310-320. PubMed ID: 28302016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacophore- based virtual screening, 3D- QSAR, molecular docking approach for identification of potential dipeptidyl peptidase IV inhibitors.
    Shah BM; Modi P; Trivedi P
    J Biomol Struct Dyn; 2021 Apr; 39(6):2021-2043. PubMed ID: 32242496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacophore generation and atom-based 3D-QSAR of N-iso-propyl pyrrole-based derivatives as HMG-CoA reductase inhibitors.
    Teli MK; K RG
    Org Med Chem Lett; 2012 Jul; 2(1):25. PubMed ID: 22747771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico approaches to predict the potential of milk protein-derived peptides as dipeptidyl peptidase IV (DPP-IV) inhibitors.
    Nongonierma AB; Mooney C; Shields DC; FitzGerald RJ
    Peptides; 2014 Jul; 57():43-51. PubMed ID: 24793774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural insights of dipeptidyl peptidase-IV inhibitors through molecular dynamics-guided receptor-dependent 4D-QSAR studies.
    Patil RB; Barbosa EG; Sangshetti JN; Zambre VP; Sawant SD
    Mol Divers; 2018 Aug; 22(3):575-583. PubMed ID: 29536226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.